Literature DB >> 11446662

Function of von Willebrand factor in children with diarrhea-associated hemolytic-uremic syndrome (D+ HUS).

A H Sutor1, K B Thomas, F H Prüfer, A Grohmann, M Brandis, L B Zimmerhackl.   

Abstract

Reports on von Willebrand factor (vWF) in hemolytic-uremic syndrome (HUS) are not unequivocal. Because of potential pathogenic implications, we examined the ability of vWF to bind to collagen in vitro, which reflects its function. Plasma vWF antigen (vWF:Ag) and collagen-binding activity (vWF:CBA) were measured by enzyme-linked immunosorbent assay in children with (1) diarrhea-associated (D+) HUS (n = 27), (2) chronic renal insufficiency (CRI) (n = 8), (3) gastroenteritis (GE) not associated with HUS (n = 15), (4) immune thrombocytopenia (ITP) (n = 40) and from controls (n = 35). Structural vWF was evaluated by multimer analysis. Children with D+ HUS had vWF:Ag of 2.53 and vWF:CBA of 1.98 U/mL. The corresponding values for patients with ITP were 1.35 and 1.82 U/mL, with CRI 1.55 and 1.55 U/mL, and with GE 1.68 and 2.10 U/mL; all values were higher than in controls (1.04 and 1.16 U/mL). The mean ratio of vWF:CBA to vWF:Ag ratio in controls was 1.13; only children with HUS had a dysfunctional vWF, as indicated by a low ratio of 0.78; the ratio was elevated in children with ITP (1.36) and GE (1.27) and was normal in those with CRI (1.06). No ultralarge molecular multimers of vWF were detected in any group, including HUS. The very high concentration of plasma vWF:Ag in HUS probably reflects endothelial cell damage or irritation. In contrast to all other groups, only children with HUS had a dysfunctional vWF, caused either by a primary (due to enterohemorrhagic Escherichia coli) or secondary (due to consumption of functionally active vWF) process. This abnormality was not obvious as structural anomaly by multimer analysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11446662     DOI: 10.1055/s-2001-15267

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

1.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Authors:  Leticia H Nolasco; Nancy A Turner; Aubrey Bernardo; Zhenyin Tao; Thomas G Cleary; Jing-Fei Dong; Joel L Moake
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

2.  Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients With Ventricular Assist Devices.

Authors:  Ulrich Geisen; Kerstin Brehm; Georg Trummer; Michael Berchtold-Herz; Claudia Heilmann; Friedhelm Beyersdorf; Johannes Schelling; Axel Schlagenhauf; Barbara Zieger
Journal:  J Am Heart Assoc       Date:  2018-01-13       Impact factor: 5.501

3.  Increased von Willebrand factor parameters in children with febrile seizures.

Authors:  Astrid Pechmann; Sven Wellmann; Benjamin Stoecklin; Marcus Krüger; Barbara Zieger
Journal:  PLoS One       Date:  2019-01-03       Impact factor: 3.240

Review 4.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.